The effects of co-prescription of pantoprazole on the clozapine metabolism / Maxim Kuzin, Georgios Schoretsanitis, Ekkehard Haen, Gerhard Dammann, Christoph Hiemke, Gerhard Gründer, Michael Paulzen
BACKGROUND: Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study was to evaluate the pantoprazole effects on clozapine metabolism. METHODS: A large therapeutic drug-monitoring database containing plasma concentrations of CLZ was analyzed. The results were stratified into four groups: a non-smoking (n=250) and a smoking group (n=326), and two groups co-medicated with pantoprazole: non-smokers (n=26) and smokers (n=29). The analysis was based on the non-parametrical Mann-Whitney U test (M-W-U) with a significance level of 0.05. RESULTS: Differences reached statistical significance for pharmacokinetic parameters between CLZ monotherapy and co-medication with pantoprazole neither in smokers nor in non-smokers (p>0.05 for M-W-U in pairwise comparisons). In patients with clozapine monotherapy, smokers had a higher daily dosage of CLZ compared to non-smokers (mean dosage 363±181 vs. 291±145 mg/day, p<0.001 for M-W-U). CONCLUSIONS: Adding pantoprazole to an ongoing treatment with clozapine does not alter the metabolism of clozapine to a significant extent..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Pharmacopsychiatry - 53(2020), 2, Seite 65-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuzin, Maxim, 1985- [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult |
|---|
| Anmerkungen: |
Gesehen am 25.01.2021 |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1055/a-1021-8827 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
174556862X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 174556862X | ||
| 003 | DE-627 | ||
| 005 | 20230426074307.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210125s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1021-8827 |2 doi | |
| 035 | |a (DE-627)174556862X | ||
| 035 | |a (DE-599)KXP174556862X | ||
| 035 | |a (OCoLC)1341389231 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuzin, Maxim |d 1985- |e verfasserin |0 (DE-588)1154710564 |0 (DE-627)1016112300 |0 (DE-576)501187200 |4 aut | |
| 245 | 1 | 4 | |a The effects of co-prescription of pantoprazole on the clozapine metabolism |c Maxim Kuzin, Georgios Schoretsanitis, Ekkehard Haen, Gerhard Dammann, Christoph Hiemke, Gerhard Gründer, Michael Paulzen |
| 264 | 1 | |c 2020 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.01.2021 | ||
| 520 | |a BACKGROUND: Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study was to evaluate the pantoprazole effects on clozapine metabolism. METHODS: A large therapeutic drug-monitoring database containing plasma concentrations of CLZ was analyzed. The results were stratified into four groups: a non-smoking (n=250) and a smoking group (n=326), and two groups co-medicated with pantoprazole: non-smokers (n=26) and smokers (n=29). The analysis was based on the non-parametrical Mann-Whitney U test (M-W-U) with a significance level of 0.05. RESULTS: Differences reached statistical significance for pharmacokinetic parameters between CLZ monotherapy and co-medication with pantoprazole neither in smokers nor in non-smokers (p>0.05 for M-W-U in pairwise comparisons). In patients with clozapine monotherapy, smokers had a higher daily dosage of CLZ compared to non-smokers (mean dosage 363±181 vs. 291±145 mg/day, p<0.001 for M-W-U). CONCLUSIONS: Adding pantoprazole to an ongoing treatment with clozapine does not alter the metabolism of clozapine to a significant extent. | ||
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Aged, 80 and over | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Antipsychotic Agents | |
| 650 | 4 | |a Clozapine | |
| 650 | 4 | |a Databases, Factual | |
| 650 | 4 | |a Drug Interactions | |
| 650 | 4 | |a Drug Monitoring | |
| 650 | 4 | |a Pantoprazole | |
| 650 | 4 | |a Proton Pump Inhibitors | |
| 650 | 4 | |a Smokers | |
| 650 | 4 | |a Young Adult | |
| 700 | 1 | |a Schoretsanitis, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Haen, Ekkehard |e verfasserin |4 aut | |
| 700 | 1 | |a Dammann, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Hiemke, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Gründer, Gerhard |e verfasserin |0 (DE-588)1078251037 |0 (DE-627)838195350 |0 (DE-576)449927644 |4 aut | |
| 700 | 1 | |a Paulzen, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacopsychiatry |d Stuttgart [u.a.] : Thieme, 1984 |g 53(2020), 2, Seite 65-70 |h Online-Ressource |w (DE-627)326977503 |w (DE-600)2041961-2 |w (DE-576)26359355X |x 1439-0795 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2020 |g number:2 |g pages:65-70 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1055/a-1021-8827 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1021-8827 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 936 | u | w | |d 53 |j 2020 |e 2 |h 65-70 |g 6 |
| 951 | |a AR | ||
| 952 | |d 53 |j 2020 |e 2 |h 65-70 |g 6 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3841964370 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 25-01-21 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2020 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_7 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1563762943 |a Gründer, Gerhard | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416467254 |a Medizinische Fakultät Mannheim | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_6 | ||